

Pathology and Diagnostic Pathology Division

1. Fujii H, Ichikawa K, Tkagaki T, Nakanishi Y, Ikegami M, Hirose S, Shimoda T. Genetic evolution of alpha-fetoprotein producing gastric cancer. *J Clin Pathol* 2003;56:942-949.
2. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. *Gastric Cancer* 2003;6:39-48.
3. Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, Sakamoto M, Tsuchiya R, Kato H, Furuta K. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. *Jpn J Clin Oncol* 2003;33:522-6.
4. Harada M, Kumemura H, Sakisaka S, Shishido S, Taniguchi E, Kawaguchi T, Hanada S, Koga H, Kumashiro R, Ueno T, Suganuma T, Furuta K, Namba M, Sugiyama T, Sata M. Wilson disease protein ATP7B is localized in the late endosomes in a polarized human hepatocyte cell line. *Int J Mol Med* 2003;11:293-8.
5. Hasegawa T, Hasegawa F, Hirose T, Sano T, Matsuno Y. Expression of smooth muscle markers in so called malignant fibrous histiocyomas. *J Clin Pathol* 2003;56:666-671.
6. Hasegawa T. World Health Organization classification of tumours, pathology and genetics: tumours of soft tissue and bone. *Lancet Oncol* 2003;4:383.
7. Hayashi I, Tsuda H, Shimoda T, Maeshima A, Kasamatsu T, Yamada T, Tsunematsu R. Difference in cytoplasmic localization pattern of neural mucin among lobular endocervical glandular hyperplasia, adenoma malignum, and common adenocarcinoma of the uterine cervix. *Virch Arch* 2003;443:752-760.
8. Kawaguchi S, Wada T, Nagoya S, Isu K, Yamashiro K, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Umeda T, Yoshikawa H, Hasegawa T. Extraskelatal myxoid chondrosarcoma. A multi-institutional study of 42 cases in Japan. *Cancer* 2003;97:1285-1292.
9. Kim YK, Mankad S, Kim SJ, Takagi G, Tamura T, Gerdes AM, Bishop SP, Kramer CM. Adding angiotensin II type 1 receptor blockade to angiotensin converting enzyme inhibition limits myocyte remodeling after myocardial infarction. *J Card Fail* 2003;9:238-245.
10. Mikami Y, Manabe T, Epstein JI, Shiraishi T, Furusato M, Tsuzuki T, Matsuno Y, Sasano H. Accuracy of Gleason grading by practicing pathologists and the impact of education on improving agreement. *Human Pathology* 2003;34:658-665.
11. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E. Osteosarcoma with cytokeratin expression: a clinicopathologic study of six cases with an emphasis on differential diagnosis from metastatic cancer. *J Clin Pathol* 2003;56:742-746.
12. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E. Prognostic relevance of rosette-like features in osteosarcoma. *J Clin Pathol* 2003;56:831-834.
13. Schlenker EH, Tamura T, Gerdes AM. Gender-specific effects of thyroid hormones on cardiopulmonary function in SHHF rats. *J Appl Physiol* 2003;6:2292-2298.
14. Sekine S, Shibata T, Matsuno Y, Maeshima A, Ishii G, Sakamoto M, Hirohashi S. β -catenin mutations in pulmonary blastomas: association with morule formation. *J Pathol* 2003;200:214-221.
15. Takei H, Asamura H, Matsuno Y. Reply to the editor. *J Thorac Cardiovascul Surg* 2003;125:

183-1184.

16. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, Hayabuchi N, Hirohashi S. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: Clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. *Am J Surg Pathol* 2003;7:937-951.
17. Tsuda H, Mikami H, Kaku T, Akiyama F, Hasegawa T, Okada S, Hayashi I, Kasamatsu T. Interobserver variation in the diagnosis of adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. *Pathol Int* 2003;53:440-449.
18. Yachida S, Fukushima N, Nakanishi Y, Akasu T, Kitamura H, Sakamoto M, Shimoda T. Alpha-fetoprotein producing carcinoma of the colon. A case report. *Dis Colon Rectum* 2003;46:826-831.
19. Yamaguchi U, Hasegawa T, Hirose T, Chuman H, Kawai A, Ito Y, Beppu Y. Low-grade malignant peripheral nerve sheath tumour: varied cytological and histological patterns. *J Clin Pathol* 2003;56:826-830.
20. Yamaguchi U, Hasegawa T, Hirose T, Fugo K, Mitsunashi T, Shimizu M, Kawai A, Ito Y, Chuman H, Beppu Y. Sclerosing perineurioma: a clinicopathological study of five cases and diagnostic utility of immunohistochemical staining for GLUT1. *Virchows Arch* 2003;443:159-163.

Diagnostic Radiology Division

21. Iinima G, Moriyama N, Miyakawa K, Yamamoto N, Fujii T, Shimada T, Ishikawa T, Ushio K. Early invasive colorectal carcinomas with submucosal invasion: Radiographic characteristics with barium double contrast. *Abdominal Imaging* 2003;28:492-504.
22. Koyama M, Johkoh T, Honda O, Tsubamoto M, Kozuka T, Tomiyama N, Hamada S, Nakamura H, Akira M, Ichikado K, Fujimoto K, Rikimaru T, Tateishi U, Muller NL. Chronic cystic lung disease: diagnostic accuracy of high-resolution CT in 92 patients. *AJR Am J Roentgenol* 2003;180:827-835.
23. Lee KS, Kim TS, Fujimoto K, Moriya H, Watanabe H, Tateishi U, Ashizawa K, Johkoh T, Kim EA, Kwon OJ. Thoracic manifestation of Wegener's granulomatosis: CT findings in 30 patients. *Eur Radiol* 2003;13:43-51.
24. Takayasu K, Mizuguchi Y, Muramatsu Y, Shimada K, Takayama T, Sato C. Neovasculature of benign thrombus of the inferior vena cava demonstrated by CT during hepatic arteriography, mimicking a small hepatocellular carcinoma. *Jpn J Clin Oncol* 2003;33:44-46.
25. Takayasu K, Mizuguchi Y, Muramatsu Y, Yamasaki S, Sugiura T, Sato C, Sakamoto M. Late complication of a large simple cyst of the liver mimicking cystadenocarcinoma after sclerotherapy. *AJR Am J Roentgenol* 2003;181:464-466.
26. Tateishi U, Gladish GW, Kusumoto M, Hasegawa T, Yokoyama R, Tsuchiya R, Moriyama N. Chest wall tumors: radiologic findings and pathologic correlation: part 1. Benign tumors. *Radiographics* 2003;23:1477-1490.
27. Tateishi U, Gladish GW, Kusumoto M, Hasegawa T, Yokoyama R, Tsuchiya R, Moriyama N. Chest wall tumors: radiologic findings and pathologic correlation: part 2. Malignant tumors. *Radiographics* 2003;23:1491-1508.
28. Tateishi U, Hasegawa T, Beppu Y, Kawai A, Moriyama N. Prognostic significance of grading

- (MIB-1 system) in patients with myxoid liposarcoma. *J Clin Pathol* 2003;56:579-582.
29. Tateishi U, Hasegawa T, Beppu Y, Satake M, Moriyama N. Primary dedifferentiated liposarcoma of the retroperitoneum. Prognostic significance of computed tomography and magnetic resonance imaging features. *J Comput Assist Tomogr* 2003;27:799-804.
 30. Tateishi U, Hasegawa T, Kusumoto M, Yamazaki N, Iinuma G, Muramatsu Y, Moriyama N. Metastatic angiosarcoma of the lung: spectrum of CT findings. *AJR Am J Roentgenol* 2003;180:1671-1674.
 31. Tateishi U, Hasegawa T, Makimoto A, Moriyama N. Adult neuroblastoma: radiologic and clinicopathologic features. *J Comput Assist Tomogr* 2003;27:321-326.
 32. Tateishi U, Hasegawa T, Miyakawa K, Sumi M, Moriyama N. CT and MRI features of recurrent tumors and second primary neoplasms in pediatric patients with retinoblastoma. *AJR Am J Roentgenol* 2003;181:879-884.
 33. Tateishi U, Hasegawa T, Muramatsu Y, Moriyama N. Hepatic metastases of soft tissue angiosarcoma: CT and MR imaging findings. *Abdom Imaging* 2003;28:660-664.
 34. Tateishi U, Hasegawa T, Satake M, Moriyama N. Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality. *J Comput Assist Tomogr* 2003;27:792-798.
 35. Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, Takei H, Maeshima A, Murayama S, Moriyama N. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. *AJR Am J Roentgenol* (in press)
 36. Takayasu K, Muramatsu Y, Mizuguchi Y, Moriyama N, Ojima H. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodule) on dynamic CT and combination of CT and angiography: experience in resected liver specimen. *Intervirolgy* (in press)

Endoscopy Division

37. Eguchi T, Gotoda T, Oda I, Hamanaka H, Hasuike N, Saito D. Is endoscopic one-piece mucosal resection essential for early gastric cancer? *Digestive Endoscopy* 2003;15(2):113-116.
38. Kondo H, Gotoda T, Ono H, Oda I, Saito D, Yoshida S. Percutaneous, traction-assisted EMR by using an insulation-tipped electrosurgical knife for early stage gastric cancer. *Gastrointest Endosc* 2003;58(7):1-5.
39. Soetikno R, Gotoda T, Soehendra N. Endoscopic mucosal resection. *Gastrointest Endosc* 2003;57:567-579.
40. Sumiyoshi T, Gotoda T, Muro K, Rembacken B, Goto M, Sumiyoshi Y, Ono H, Saito D. Morbidity and mortality after self-expandable metallic stent placement in patients with regressive or current esophageal cancer after chemoradiotherapy. *Gastrointest Endosc* 2003;57(7):882-885.
41. Torii N, Nozaki T, Masutani M, Nakagama H, Sugiyama T, Saito D, Asaka M, Sugimura T, Miki K. Spontaneous mutations in Helicobacter pylori rpsL gene. *Mutation Research* 2003;535:141-145.

Breast and Medical Oncology Division

42. Aihara T, Takatsuka Y, Itoh K, Sasaki Y, Katsumata N, Watanabe T, Noguchi S, Horikoshi N, Tabei T, Sonoo H, Hiraki S, Inaji H. Phase II study of concurrent administration of doxorubicin

and docetaxel as first-line chemotherapy for metastatic breast cancer. *Oncology* 2003;64:124-130.

43. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. *Br J Cancer* 2003;89 suppl 3:S9-S15.
44. Kouno T, Katsumata N, Mukai H, Ando M, Watanabe T. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan. *Jpn J Clin Oncol* 2003;33:309-313.
45. Mukai H, Watanabe T, Ando M, Katsumata N. Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel. *Int J Clin Oncol* 2003;8:23-25.
46. Okamoto, T, Shimozuma K, Katsumata N, Koike M, Hisashige A, Tanaka K, Ohsumi S, Saito M, Shikama N, Mitsumori M, Yamauchi C, Watanabe T; Task force of the Japanese Breast Cancer Society for "The Development of Guidelines for Quality of Life Assessment Studies of Breast Cancer Patients". Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. *Breast Cancer* 2003;10:204-213.

Gastrointestinal Oncology Division

47. Hosokawa A, Yamada Y, Shimada Y, Muro K, Matsumura Y, Shirao K, Fujita S, Akasu T, Moriya Y. Weekly hepatic arterial infusion of 5-Fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer. *Jpn J Clin Oncol* 2003;33:132-135.
48. Inoue A, Yamada Y, Matsumura Y, Shimada Y, Muro K, Gotoh M, Hamaguchi T, Mizuno T, Shirao K. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. *Support Care Cancer* 2003;11:528-532.
49. Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Suzuki H, Sugiyama Y, Ozawa S, Sawada J. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in irinotecan-administered Japanese cancer patients. *Drug Metabolism and Pharmacokinetics* 2003;18(3):212-217.
50. Ohtsu A, Boku N, Yoshioka T, Hyodo I, Shirao K, Shimada Y, Saitoh S, Nakamura A, Yamamichi N, Yamamoto S, Yoshida S. Phase II Study of Irinotecan in combination with 120-h infusion of 5-Fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). *J Clin Oncol* 2003;22(1):28-32.
51. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer; The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21(1):54-59.
52. Su-Ryang Kim, Nakamura T, Saito Y, Sai K, Nakajima N, Saito H, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S, Sawada J. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxyl esterase 2 (hCE-2). *Drug Metabolism and Pharmacokinetics* 2003;18(5):327-332.
53. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S. Plasma concentrations of 5-fluorouracil and F-2'-alanine following oral administration of S-1, a

- dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. *Br J Cancer* 2003;89:816-820.
54. Yamada Y, Shirao K, Hyodo I, Arai Y, Denda T, Ando T, Ohtsu A. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. *Cancer Chemother Pharmacol* 2003;52:125-130.
55. Yamada Y, Yasui H, Goto A, Arai T, Ura T, Hamaguchi T, Muro K, Shimada Y, Shirao K. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. *Int J Clin Oncol* 2003;8:374-380.

Hematology Division

56. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y. Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. *Int J Hematol* 2003;78:357-361.
57. Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K and members for the Lenograstim/Lymphoma Study Group. A dose-finding study of glycosylated G-CSF (lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. *Jpn J Clin Oncol* 2003;33:78-85.
58. Tanioka F, Tamashima S, Shimizu S, Kobayashi H, Kobayashi Y, Sugimura H. A case of primary plasma cell leukemia with hairy-cell morphology and lambda-type Bence-Jones protein: immunohistochemical and molecular analysis. *Jpn J Clin Oncol* 2003;33:232-237.
59. Tobinai K, Uike N, Saburi Y, Chou T, Etoh T, Masuda M, Kawano F, Matsuoka M, Kuzume T, Makino T, Asano Y, Tamura K, Ohashi Y, and members for the Cladribine/ATL Study Group, Japan. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. *Int J Hematol* 2003;77:512-517.
60. Tobinai K: Chemotherapy of ATL. In: Sugamura K, Uchiyama T, Matsuoka M, Kannagi M, editors. Two Decades of Adult T-Cell Leukemia and HTLV-I Research. Progress in Basic Research and Its Implications in Clinical Advances. *Gann Monograph on Cancer Research*, No. 50, Japan Scientific Society Press, Tokyo: 2003;263-276.
61. Tobinai K. Monoclonal antibodies for the treatment of hematological malignancies: Clinical trials in Japan. *Cancer Chemother Pharmacol* 2003;52 (Suppl 1):S90-S96.
62. Tobinai K. Rituximab and other emerging monoclonal antibodies as a molecular target-based therapy of lymphoma. *Int J Clin Oncol* 2003;8:212-223.
63. Tsukasaki K, Tobinai K, Shimoyama M, Tajima K, Kozuru M, Uike N, Yamada Y, Tomonaga M, Araki K, Kasai M, Takatsuki K, Tara M, Hotta T and members of the Lymphoma Study Group of the Japan Clinical Oncology Group. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia/lymphoma: Japan Clinical Oncology Group Study 9109. *Int J Hematol* 2003;77:164-170.
64. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y, and Members for the IDEC-C2B8 Study Group in Japan. Japanese multicenter phase II and pharmacokinetic

study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. *Ann Oncol* (in press)

65. Tobinai K, Watanabe T, Jaffe ES. HTLV-I-Associated Adult T-cell Leukemia-Lymphoma. In: Mauch PM, Armitage JO, Harris NL, Coiffier B, Dalla-Favera R, editors. *Non-Hodgkin's Lymphomas*. Baltimore: Lippincott Williams & Wilkins (in press)
66. Tobinai K, Watanabe T. Adult T-cell leukemia-lymphoma. In: Abeloff MD, Armitage JO, Kastan M, Niederhuber JE, editors. *Clinical Oncology*, 3rd edition. Philadelphia: W.B. Saunders, Elsevier Science (in press)

Hematopoietic Stem Cell Transportation Team

67. Kami M, Hamaki T, Miyakoshi S, Murashige N, Kanda Y, Tanosaki R, Takaue Y, Taniguchi S, Hirai S, Ozawa K, Kasai M. Allogeneic hematopoietic stem-cell transplantation for the treatment of adult T-cell leukemia/lymphoma. *Br J Haematol* 2003;120:304-309.
68. Kami M, Takaue Y. Development of reduced-intensity hematopoietic stem cell transplantation (RIST) in the National Cancer Center Hospital, Japan. *Therapeutic Apheresis Dialysis* 2003;7: 318-328.
69. Kato K, Ikarashi Y, Sugahara T, Yasumoto A, Sancho D, Yoshida M, Takaue Y, Kobayashi Y, Sanchez-Madrid F, Wakasugi H. U5A2-13, an antigen originally found on mouse NK-like T cells, is an early inducible cell surface antigen during lymphoid activation. *Cell Immunol* 2003;221: 27-136.
70. Kim SW, Kami M, Urahama N, Yamamoto R, Hori A, Imataki O, Kanda Y, Tanosaki R, Mineishi S, Takaue Y, Honda O. Feasibility of Acute Physiology and Chronic Health Evaluation (APACHE) II and III score-based screening in patients receiving allogeneic hematopoietic stem cell transplantation. *Transplantation* 2003;75:566-570.
71. Kojima R, Kami M, Kim SW, Murashige N, Kishi Y, Hori A, Imataki O, Hamaki T, Sakiyama M, Arima F, Heike Y, Tanosaki R, Mineishi S, Takaue Y. Induction of graft-versus-autoimmune disease (GVA) effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003;32:439-442.
72. Mineishi S, Kanda Y, Saito T, Nakai K, Makimoto A, Masahiro Kami M, Tanosaki R, Wakasugi H, Tobinai K, Takaue Y. Impact of GVHD in reduced-intensity stem cell transplantation for patients with hematological malignancies. *Br J Hematol* 2003;121:296-303.
73. Nakai K, Mineishi S, Kami M, Kanda Y, Tanosaki R, Takaue Y. The feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation from a related donor with HLA one-antigen with or without one-allele mismatch. *Haematologica* 2003;88:115-117.
74. Saito T, Kanda Y, Kato K, Nakai K, SW Kim, Arima F, Kami M, Tanosaki R, Tobinai K, Wakasugi H, Heike Y, Mineishi S, Takaue Y. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and anti-thymocyte globulin: serial comparison with conventional myeloablative transplantation. *Bone Marrow Transplant* 2003;32:601-608.
75. Tanimoto T, Kusumi E, Hamaki T, Ueyama J, Miyakoshi S, Morinaga S, Kami M, Kanda Y, Ando T, Yoshihara S, Kim SW, Nakai K, Tobinai K, Tanosaki R, Mineishi S, Takaue Y, Muto Y. High

- complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. *Bone Marrow Transplant* 2003;32:131-137.
76. Urahama N, Tanosaki R, Kami M, Iijima K, Chizuka A, Kim SW, Hori A, Kojima R, Imataki O, Makimoto A, Mineishi S, Takaue Y. Transfusion-related acute lung injury (TRALI) after the infusion of bone marrow cells in a patient with acute lymphoblastic leukemia. *Transfusion* 2003;43:1553-1557.
 77. Yamamoto R, Kusumi E, Kami M, Yuji K, Hamaki T, Saito A, Murashige N, Hori A, Kim SW, Makimoto A, Ueyama J, Tanosaki R, Miyakoshi S, Mori S, Morinaga S, Heike Y, Taniguchi S, Masuo S, Takaue Y, Muto Y. Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003;32:1089-1095.
 78. Hamaki T, Kami M, Igarashi M, Kusumi E, Arase Y, Ishibashi T, Shimamura K, Miyakoshi S, Morinaga S, Takaue Y, Hayashi M, Mutou Y. Non-myeloablative hematopoietic stem-cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment. *Leuk Lymphoma* (in press)
 79. Hamaki T, Kami M, Kim SW, Onishi Y, Kishi Y, Murashige N, Hori A, Kojima R, Sakiyama M, Imataki O, Heike Y, Tanosaki R, Masuo S, Miyakoshi S, Taniguchi S, Tobinai K, Takaue Y. Reduced-intensity stem-cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. *Bone Marrow Transplant* (in press)
 80. Hamaki T, Kami M, Momomura SI, Mineishi S, Kusumi E, Kanda Y, Ueyama JI, Miyakoshi S, Morinaga SI, Takaue Y, Mutou Y. Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha. *Am J Hematol* (in press)
 81. Harashima N, Kurihara K, Utunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T, Takaue Y, Okamura J, Kannagi M. Graft-versus-human T-cell leukemia virus type-I response in adult T-cell leukemia patients following non-myeloablative hematopoietic stem cell transplantation. *Cancer Res* (in press)
 82. Hori A, Kami M, Kim SW, Chizuka A, Kojima R, Imataki O, Sakiyama M, Hamaki T, Onishi Y, Usubuchi N, Kishi Y, Murashige N, Tajima K, Miyakoshi S, Heike Y, Masuo S, Taniguchi S, Takaue Y. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. *Biol Blood Marrow Transplant* (in press)
 83. Hori A, Kami M, Kim SW, Murashige N, Sakiyama M, Kojima R, Hamaki T, Makimoto A, Takaue Y. Urgent need for a validated tumor response evaluation system for use in immunotherapy. *Bone Marrow Transplant* (in press)
 84. Hori A, Kami M, Kim SW, Kojima R, Urahama N, Imataki O, Murashige N, Makimoto A, Kanda Y, Heike Y, Tanosaki R, Mineishi S, Takaue Y. Balance between acute graft-versus-host disease and graft-versus-tumor effect after reduced-intensity transplantation for metastatic renal cell carcinoma: Report of two cases. *Hematology Journal* (in press)
 85. Hori S, Takei M, Heike Y, Maruyama M, Inoue Y, Lee YJ, Kim HJ, Harada Y, Kawai H, Shimosaka A, Kami M, Tanosaki R, Kato K, Wakasugi H, Saito S, Takaue Y, Kakizoe T. Freeze-thawing

- procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes. *J Immunother* (in press)
86. Imataki O, Kim SW, Kami M, Gotoh M, Komaba S, Kasai M, S Hashino S, Naito K, Masuda M, Anan K, Teshima H, Togitani K, Inoue T, Nishimura M, Adachi Y, Fukuhara T, Yamashita T, Uike N, Kobayashi Y, Hamaguchi M, Higuchi M, Kawakami K, Takaue Y. A nationwide survey of deep fungal infections and antifungal prophylaxis for patients undergoing hematopoietic stem-cell transplantation (HSCT): Revisit of the Guidelines from the Centers for Disease Control and Prevention (CDC). *Bone Marrow Transplant* (in press)
 87. Imataki O, Kim SW, Kojima R, Hori A, Hamaki T, Sakiyama M, Murashige N, Satoh M, Kami M, Takaue Y. Life-threatening hypothyroidism associated with administration of cyclosporine in a patient treated with reduced-intensity hematopoietic stem cell transplantation for metastatic renal cell carcinoma. *Transplantation* (in press)
 88. Kami M, Hori A, Takaue Y, Mutou Y. Gastrointestinal tract is a common target of invasive aspergillosis in patients receiving cytotoxic chemotherapy for hematological malignancy. *Clin Inf Dis* (in press)
 89. Kami M, Machida U, Okuzumi K, Matsumura T, Mori S, Hori A, Kashima T, Kanda Y, Takaue Y, Sakamaki H, Hirai H, Yoneyama A, Mutou Y. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with hematological malignancy. *Br J Haematol* (in press)
 90. Kamitsuji Y, Mori S, Kami M, Yamada H, Shirakawa K, Kishi Y, Murashige N, Kim SW, Heike Y, Takaue Y. Fatal deep vein thrombosis after allogeneic reduced-intensity hematopoietic stem-cell transplantation for the treatment of metastatic gastric cancer. *Ann Hematol* (in press)
 91. Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, Chizuka A, Niiya H, Suenaga K, Nakai K, Takeuchi T, Makimoto A, Tanosaki R, Kami M, Tanaka Y, Fujita S, Watanabe T, Kobayashi Y, Tobinai K, Takaue Y. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* (in press)
 92. Kim SW, Kami M, Kobayashi K, Takaue Y, Honda O. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomized controlled trial. *Lancet* (in press)
 93. Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Kim SW, Heike Y, Ueyama J, Miyakoshi S, Tanosaki R, Morinaga S, Mineishi S, Muto Y, Takaue Y. Feasibility of reduced-intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. *Bone Marrow Transplant* (in press)
 94. Kusumi E, Miyakoshi S, Murashige N, Hamaki T, Kim SW, Yuji K, Kami M, Ueyama J, Morinaga S, Takaue Y, Muto Y. Successful reduced-intensity stem cell transplantation (RIST) with mismatched cord blood in a 70-year-old patient with severe aplastic anemia. *Bone Marrow Transplant* (in press)
 95. Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, Gondo H, Harada M, Sakamaki H, Yajima T, Iwao Y, Hibi T, Okamoto S. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* (in press)

96. Nakai K, Mineishi S, Kami M, Saito T, Kamijo K, Hori A, Yamamoto R, Imataki O, Hamaki T, Yoshihara S, Ohnishi M, Kim SW, Ando T, Matsubara H, Kanda Y, Makimoto A, Tanosaki R, Kanai S, Heike Y, Tobinai K, Ohnishi T, Kawano Y, Wakasugi H, Takaue Y. Anti-thymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction. *Transplantation* (in press)
97. Yamasaki S, Ohno Y, Taniguchi S, Yoshida T, Hayashi S, Ogawa H, Shimazaki C, Takahashi S, Kasai M, Wake A, Nishimura M, Tokunaga K, Gondo H, Takaue Y, Harada M, Mineishi S. Allogeneic peripheral blood stem cell transplantation from 2- or 3-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies. *Bone Marrow Transplant* (in press)

Hepatobiliary and Pancreatic Oncology Division

98. Morizane C, Okada S, Okusaka T, Hideki U, Saisho T. Phase II study of cisplatin, epirubicin, and continuous-infusion of 5-fluorouracil (5-FU) (CEF therapy) for advanced biliary tract cancer. *Oncology* 2003;64:475-476.
99. Ikeda, M., Maeda, S., Shibata, J., Muta, R., Ashihara, H., Tanaka, M., Fujishiro, S., and Tomita, K. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. *Oncology* (in press)
100. Okusaka T, Okada, D., Nakanishi, T., Fujiyama, S., and Kudo, Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. *Invest New Drug* (in press)
101. Okusaka, T, Matsumura, Y, and Aoki, K. New approach for pancreatic cancer in Japan. *Cancer Chemother Pharmacol* (in press)
102. Okusaka, T., and Kosuge, T. Systemic chemotherapy for pancreatic cancer. *Pancreas* (in press)

Pediatric Oncology

103. Matsubara H, Makimoto A, Higa T, Kanda Y, Kami M, Tanosaki R, Mineishi S, Ohira M, Takaue Y. Meningoencephalitis caused by methicillin-resistant *Staphylococcus aureus* in a recipient of allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2003;31:65-67.
104. Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, Ohira M, Yokoyama R, Beppu Y, Takaue Y. Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy. *Pediatr Hematol Oncol* 2003;20:201- 210.

Psycho-Oncology Division

105. Akechi T, Nakano T, Akizuki N, Nakanishi T, Yoshikawa E, Okamura H, Uchitomi Y. Psychiatric evaluation of competency in cancer patients. *Int J Psychiatry Clin Pract.* 2003;7:101-106.
106. Akechi T, Nakano T, Akizuki N, Okamura M, Sakuma K, Nakanishi T, Yoshikawa E, Uchitomi Y. Somatic symptoms for diagnosing major depression in cancer patients. *Psychosomatics* 2003;44: 244-8.
107. Akechi T, Sakuma K, Okamura M, Akizuki N, Oba A, Nakano T, Uchitomi Y. Trauma in a nurse

after patient suicide. *Psychosomatics* 2003;44:522-3.

108. Akizuki N, Akechi T, Nakanishi T, Yoshikawa E, Okamura M, Nakano T, Murakami Y, Uchitomi Y. Development of a brief screening interview for adjustment disorders and major depression in patients with cancer. *Cancer* 2003;97:2605-2613.
109. Fujimori M, Oba A, Koike M, Okamura M, Akizuki N, Kamiya M, Akechi T, Sakano Y, Uchitomi Y. Communication skills training for Japanese oncologists on how to break bad news. *J Cancer Educ* 2003;18:194-201.

Thoracic Oncology Division

110. Ando Y, Ohtsu T, Ando M, Ohyanagi F, Nagashima F, Narabayashi M, Saijo N, Sasaki Y. Re: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. *J Natl Cancer Inst* 2003;95:1638-1640.
111. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2003;21(12):2237-2246.
112. Hotta K, Sekine I, Suzuki K, Kondo H, Asamura H, Sumi M, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N, Tsuchiya R. Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer. *Thorac Cardiovasc Surg* 2003;51(5):283-287.
113. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S, Sawada J. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. *J Pharmacol Exp Ther* 2003;306(2):688-693.
114. Jinno H, Saeki M, Tanaka-Kagawa T, Hanioka N, Saito Y, Ozawa S, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. *Drug Metab Dispos* 2003;31(5):528-32.
115. Kanzawa F, Akiyama Y, Saijo N, Nishio K. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. *Lung Cancer* 2003;40(3):325-32.
116. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. *Ann Oncol* 2003;14(6):922-30.
117. Nakamura Y, Kunitoh H, Kubota K, Sekine I, Yamamoto N, Tamura T, Kodama T, Saijo N. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m² in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy. *Am J Clin Oncol* 2003;26(5):459-64.
118. Natsume T, Watanabe J, Koh Y, Fujio N, Ohe Y, Horiuchi T, Saijo N, Nishio K, Kobayashi M.

- Antitumor activity of TZZ-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. *Cancer Sci* 2003;94(9):826-33.
119. Ohe Y, Ishizuka N, Tamura T, Sekine I, Nishiwaki Y, Saijo N. Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). *Cancer Sci* 2003;94(8):729-34.
 120. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada JI. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. *Pharmacogenetics* 2003;13(12):741-757.
 121. Saijo N, Nishio K, Tamura T. Translational and clinical studies of target-based cancer therapy. *Int J Clin Oncol* 2003;8(4):187-92.
 122. Saijo N, Tamura T, Nishio K. Strategy for the development of novel anticancer drugs. *Cancer Chemother Pharmacol* 2003;52 Suppl 1:S97-101.
 123. Saijo N. Progress in treatment of small-cell lung cancer: role of CPT-11. *Br J Cancer* 2003;89(12):2178-83.
 124. Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Goto K, Kodama T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yoshimura K, Saijo N. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. *Br J Cancer* 2003;88(6):808-13.
 125. Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, Negoro S, Yokoyama A, Matsui K, Ohsaki Y, Nakano T, Saijo N; Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). *Ann Oncol* 2003;14(5):709-14.
 126. Tsunoda T, Koh Y, Koizumi F, Tsukiyama S, Ueda H, Taguchi F, Yamaue H, Saijo N, Nishio K. Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis. *Int J Oncol* 2003;23(1):49-59.
 127. Usuda J, Inomata M, Fukumoto H, Iwamoto Y, Suzuki T, Kuh HJ, Fukuoka K, Kato H, Saijo N, Nishio K. Restoration of p53 gene function in 12-O-tetradecanoylphorbol 13-acetate-resistant human leukemia K562/TPA cells. *Int J Oncol* 2003;22(1):81-6.
 128. Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saijo N. Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients. *Cancer Sci* 2003;94(11):1015-20.
 129. Yamamoto N, Tamura T, Kamiya Y, Ono H, Kondoh H, Shirao K, Matsumura Y, Tanigawara Y, Shimada Y. Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors. *Jpn J Clin Oncol* 2003;33(6):302-8.
 130. Yamanaka R, Akutagawa S, Taguchi F, Yajima N, Tsuchiya N, Uzuka T, Morii K, Takahashi H, Tanaka R, Saijo N, Nishio K. Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles.

Int J Oncol 2003;23(4):913-23.

131. Yanagitani N, Kohno T, Kim JG, Kunitoh H, Tamura T, Takei Y, Tsuchiya S, Saito R, Yokota J. Identification of D19S246 as a novel lung adenocarcinoma susceptibility locus by genome survey with 10-cM resolution microsatellite markers. *Cancer Epidemiol Biomarkers Prev* 2003;12(4): 366-71.
132. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. *Hum Mutat* (in press)
133. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. *Int J Cancer* (in press)
134. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H. Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group. *J Clin Oncol* (in press)
135. Ohe Y, Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, Nokihara H, Kunitoh H, Saijo N, Aono H, Watanabe K, Tango M, Yokoyama A, Nishiwaki Y. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. *Ann Oncol* (in press)
136. Taguchi F, Kusaba H, Asai A, Iwamoto Y, Yano K, Nakano H, Mizukami T, Saijo N, Kato H, Nishio K. hnRNP L enhances sensitivity of the cells to KW-2189. *Int J Cancer* (in press)

Radiation Oncology Division

137. Ikeda H. Special report: Non-invasive management of invasive bladder cancer: Lectures by Professor William U. Shipley. *Jpn J Clin Oncol* 2003;33:592-594.
138. Ito Y, Ohtsu A, Ishikura S, Boku N, Nihei K, Ogino T, Ikeda H: Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer. *Jpn J Clin Oncol* 2003;33: 180-185.
139. Kinoshita K, Teshima T, Ohno Y, Inoue T, Yamashita T, Hiraoka M, Mitsuhashi N, Sumi M. Logical checking function increases the accuracy of data entry in the patterns of care study. *Strahlenther Onkol.* 2003;179:107-112.
140. Nakamura K, Teshima T, Takahashi Y, Imai A, Koizumi M, Mitsuhashi N, Inoue T. Japanese PCS Working Subgroup of Prostate Cancer. Radical radiation therapy for prostate cancer in Japan: a Patterns of Care Study report. *Jpn J Clin Oncol* 2003;33:122-126.
141. Sugiyama H, Teshima T, Ohno Y, Inoue T, Takahashi Y, Oshima A, Sumi M, Uno T, Ikeda H and the Japanese PCS Working Subgroup for Lung Cancer: The Patterns of Care Study and regional cancer registry for non-small-cell lung cancer in Japan. *Int J Radiat Oncol Biol Phys* 2003;56:

- 1005-1012.
142. Tokuyue K, Sumi M, Kagami Y, Murayama S, Ikeda H, Ikeda M, Okusaka T, Ueno H, Okada S. Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. *Radiother Oncol* 2003;67:327-330.
143. Uno T, Sumi M, Sawa Y, Teshima T, Hara R, Ikeda H, Inoue T, Japanese PCS Working Subgroup of Lung Cancer: Process of care and preliminary outcome in limited-stage small-cell lung cancer: results of the 1995-1997 Patterns of Care Study in Japan. *Int J Radiat Oncol Biol Phys* 2003;55:626-632.
144. Sumi M, Uno T, Ikeda H, Teshima T, Inoue T, Sawa Y, Suzuki Y. The patterns of care study for non-small cell lung cancer patients treated with radiation therapy in Japan: comparison of the process between 1995-1997 survey and 1999-2001 survey. *Int J Radiat Oncol Biol Phys* (in press)

Breast Surgery Division

145. Akashi-Tanaka S, Fukutomi T. Role of computed tomography on selection of the treatment of breast cancer. *Breast Cancer* 2003;10(3):198-203
146. Akashi-Tanaka S, Fukutomi T, Sato N, Iwamoto E, Watanabe T, Katsumata N, Ando M, Miyakawa K, Nanasawa T, Hasegawa T. The use of contrast-enhanced computed tomography prior to neoadjuvant chemotherapy to identify patients likely to be treated safely with breast conserving surgery. *Ann Surg* (in press)
147. Asada K, Fukutomi T. Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. *Oncology* (in press)
148. Kinoshita T, Fukutomi T and Kubochi K, MR Imaging of Benign Pyllodes Tumor of the Breast. *Breast* (in press)
149. Kinoshita T, Fukutomi T, Iwamoto E, and Akashi S, Prognosis of Breast Cancer Patients with Family History Classified According to the Menopausal Status. *Breast J* (in press)

Colorectal Surgery Division

150. Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S. Prognostic significance of dysadherin expression in advanced colorectal carcinoma. *Br J Cancer* 2003;88:726-32.
151. Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. *J Surg Oncol* 2003;84:127-31.
152. Fujita S, Yamamoto S, Akasu T, Moriya Y. Lateral pelvic lymph node dissection for advanced lower rectal cancer. *Br J Surg* 2003;90:1580-5.
153. Moriya Y, Akasu T, Fujita S, Yamamoto S. Aggressive surgical treatment for patients with T4 rectal cancer. *Colorectal Dis* 2003;5:427-31.
154. Sumitsuji I, Sugano K, Matsui T, Fukayama N, Yamaguchi K, Akasu T, Fujita S, Moriya Y, Yokoyama R, Nomura S, Yoshida T, Kodama T, Ogawa M. Frequent genomic disorganization of MLH1 in hereditary non-polyposis colorectal cancer (HNPCC) screened by RT-PCR on puromycin treated samples. *J Med Genet* 2003;40:e30.

155. Yamamoto S, Akasu T, Fujita S, Moriya Y. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. *Jpn J Clin Oncol* 2003;33:33-7.
156. Kubota K, Akasu T, Fujita S, Sugihara K, Moriya Y, Yamamoto S. Clinical and pathological prognostic indicators with colorectal mucinous carcinomas. *Hepato-Gastroenterol* (in press)
157. Yamamoto S, Akasu T, Fujita S, Moriya Y. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: Is follow-up by CEA justified? *Hepato-Gastroenterol* (in press)

Dermatology Division

158. Kamiya M, Ichiki Y, Kamiya H, Yamamoto A, Kitajima Y. Detection of nonmelanoma skin cancer micrometastases in lymph nodes by using reverse transcriptase-polymerase chain reaction for keratin 19 mRNA. *Br J Dermatol* 2003;149:998-1005.
159. Nagayama H, Sato K, Morishita M, Uchimarui K, Oyaizu N, Inazawa T, Yamasaki T, Emoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA and Yamashita N. Result of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. *Melanoma Res* 2003;13:521-530.

Esophageal Surgery Division

160. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H. Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204. *J Clin Oncol* 2003;21:4592-6.
161. Fang W, Kato H, Tachimori Y, Igaki H, Sato H, Daiko H. Analysis of pulmonary complications after three-field lymph node dissection for esophageal cancer. *Ann Thorac Surg* 2003;76:903-8.
162. Igaki H, Kato H, Tachimori Y, Nakanishi Y. Prognostic evaluation of patients with clinical T1 and T2 squamous cell carcinomas of the thoracic esophagus after 3-field lymph node dissection. *Surgery* 2003;133:368-74.
163. Yokoyama T, Yokoyama A, Kato H, Tsujinaka T, Muto M, Omori T, Haneda T, Kumagai Y, Igaki H, Yokoyama M, Watanabe H, Yoshimizu H. Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. *Cancer Epidemiol Biomarkers Prev* 2003;12:1227-33.

Gastric Surgery Division

164. Katai H, Sano T, Fukagawa T, Shinohara H, Sasako M. A prospective study of proximal gastrectomy for early gastric cancer in the upper third of the stomach. *Br J Surg* 2003;90:850-3.
165. Liu Y, Yoshimura K, Yamaguchi N, Shinmura K, Yokota J, Katai H. Causation of Borrmann type 4 gastric cancer: heritable factors or environmental factors. *Gastric Cancer* 2003;6:17-23.
166. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S, and the Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, cytosine

- arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. *J Clin Oncol* 2003;21:2282-7.
167. Sasako M, Mann B: Gastric cancer In: Majid AA and Kingsnorth AN editors. *Advanced Surgical Practice*, San Francisco, Greenwich Medical Media 2003;63-72.
168. Sasako M. D2 Nodal Dissection. *Operative Techniques in General Surgery* 2003;5:36-49.
169. Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Katai H, Yoshimura K, Terada M, Perucho M, Yoshida T. The genomic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer. *Gastroenterology* 2003;125:1330-40.
170. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: results of morbidity and mortality of a prospective randomized controlled trial (JCOG 9501) comparing D2 and extended para-aortic lymphadenectomy. *J Clin Oncol* (in press)

Gynecology Division

171. Kasamatsu T, Onda T, Katsumata N, Sawada M, Yamada T, Tsunematsu R, Ohmi K, Sasajima Y, Matsuno Y. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. *Br J Cancer* 2003;88:245-250.
172. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, Yamada T, Kikuchi Y, Honjo H, and Matsubara O. Different expression patterns of KIT, EGFR, and HER-2(c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. *Cancer Sci* 2003;94:986-991.

Hepatobiliary and Pancreatic Surgery Division

173. Nunobe S, Fukushima N, Yachida S, Shimada K, Kosuge T, Sakamoto M. Clear cell endocrine tumor of the pancreas which is not associated with von Hippel-Lindau disease: report of a case. *Surg Today* 2003;33(6):470-4.
174. Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T, Makuuchi M. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. *Ann Surg* 2003;238(1):73-83.
175. Xiong HQ, Abbruzzese JL, Esumi H, Kosuge T, Kakizoe T, Sugimura T. Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic cancer. *Jpn J Clin Oncol* 2003;33(5):246-53.
176. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, Ojima H, Sakamoto M, Takayama T, Makuuchi M. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. *Jpn J Clin Oncol* 2003;33(6):283-7.
177. K Shimada, T Kosuge, J Yamamoto, S Yamasaki, and M Sakamoto. Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis. *Hepatogastroenterology* (in press)

Neurosurgery Division

178. Fujimaki T, Ohwaki K, Kayama T, Matsutani M, Tanaka R, Ushio T, Yamashita J, Yoshimine T,

Yoshimoto T, Nomura K.. Prognostic significant of the extent of tumor and surgical excision in glioma patients: A prospective multi-institutional study. *Neuro-Oncology* 2003;9:391.

179. Nomura K. The Committee of Brain Tumor Registry of Japan. Report of brain tumor registry of Japan (1969-1996) 11th edition. *Neurol Med Chir (Tokyo)* 2003;43(Suppl):1-111.
180. Shibui S, The members of JCOG-BTSG. A randomized controlled trial on malignant brain tumors. The activities of Japan Clinical Oncology Group (JCOG)-Brain Tumor Study Group (BTSG). *Neurol Med Chir* (in press)

Ophthalmology Division

181. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. *Jpn J Clin Oncol* 2003;33:601-607.
182. Suzuki S. Management of intraocular retinoblastoma and ocular prognosis. *Int J Clin Oncol* (in press)

Thoracic Surgery

183. Asamura H, Suzuki K, Watanabe S, Matsuno Y, Maeshima A, Tsuchiya R. A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions. *Ann Thorac Surg* 2003;76:1016-1022.
184. Hishida T, Hasegawa T, Asamura H, Kusumoto M, Maeshima A, Matsuno Y, Suzuki K, Kondo H, Tsuchiya R. Malignant glomus tumor of the lung. *Pathol Int* 2003;53:632-636.
185. Nakagawa K, Asamura H, Matsuno Y, Suzuki K, Kondo H, Maeshima A, Miyaoka E, Tsuchiya R. Thymoma: a clinicopathologic study based on the new World Health Organization classification. *J Thorac Cardiovasc Surg* 2003;126:1134-1140.
186. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathological Features of Peripheral Squamous Cell Carcinoma of the Lung. *Ann Thorac Surg* (in press)
187. Sakurai H, Hasegawa T, Watanabe S, Suzuki K, Asamura H, Tsuchiya R. Inflammatory myofibroblastic tumor of the lung. *Eur J Cardiothorac Surg* (in press)
188. Sakurai H, Kondo H, Sekiguchi A, Naruse Y, Makuuchi H, Suzuki K, Asamura H, Tsuchiya R. Left Pneumonectomy for Lung Cancer After Correction of Contralateral Partial Anomalous Pulmonary Venous Return. *Ann Thorac Surg* (in press)
190. Sakurai H, Maeshima A, Watanabe S, Suzuki K, Tsuchiya R, Matsuno Y, Asamura H. Grade of stromal invasion in small adenocarcinoma of the lung: Histopathological minimal invasion and prognosis. *Am J Surg Pathol* (in press)

Urology Division

191. Akaza H, Koiso K, Ozono S, Kuroda M, Kameyama S, Okajima E, Kotake T, Kakizoe T, Kawabe K and the PMCIJ-9 Study Group in Japan. A clinical study of PMCIJ-9 (Bacillus-Calmette-Guerin Connaught stain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. *Jpn J Clin Oncol* 2003;33:382-390.
192. Horikawa Y, Sugano K, Shigyo M, Yamamoto H, Nakazono M, Fujimoto H, Kanai Y, Hirohashi S, Kakizoe T, Habuchi T and Kato T. Hypermethylation of an e-cadherin (*CDH1*) promoter region

- in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. *J Urol* 2003;169:1541-1545.
193. Kakizoe T. Reconstruction of the urinary tract after cystectomy for transitional cell carcinoma of the bladder. *Proc. Japan Acad* 2003;79:190-196.
194. Mitsuhashi M, Wanibuchi H, Wei M, Doi K, Morimura K, Masuda C, Wada S, Nakatani T, Kakizoe T and Fukushima S. No inhibition of urinary bladder carcinogenesis in rats with intravesical instillation α -Galactosylceramide. *Asian Pacific J Cancer Prev* 2003;4:45-50.
195. Mitsuhashi M, Wanibuchi H, Wei M, Doi K, Morimura K, Masuda C, Wada S, Nakatani T, Kakizoe T and Fukushima S. Lack of inhibition of BBN-induced bladder carcinogenesis in C57BL/6 mice by intravesical instillation of KRN 7000. *J Toxicol Pathol* 2003;16:19-23.
196. Nakagawa T, Kanai Y, Saito Y, Kitamura T, Kakizoe T and Hirohashi S. Increased DNA Methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder. *J Urol* 2003;170: 2463-2466.
197. Fujimoto H, Okajima E, Kawashima K and Kakizoe T. Clinicopathological statistics on registered prostate cancer patients in Japan: 2,000's report from Japanese Urological Association. *Int J Urol* (in press)
198. Kitamura H, Fujimoto H, Tobisu K, Mizuguchi Y, Maeda T, Matsuoka N, Komiyama M, Nakagawa T and Kakizoe T. Dynamic Computerized Tomography and Color Doppler Ultrasound of Renal Parenchymal Neoplasms: Correlations with Histopathological Findings. *Jpn J Clin Oncol* (in press)